Cargando…
MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma
BACKGROUND: This prospective study was designed to investigate the association between ten circulating inflammatory biomarkers and the risk for early stage lung adenocarcinoma. METHODS: All inflammatory biomarkers were measured in 228 patients with early stage (IA to IIB) lung adenocarcinoma and 228...
Autores principales: | Zhang, Yanwei, Yu, Keke, Hu, Song, Lou, Yuqing, Liu, Chunxing, Xu, Jianlin, Li, Rong, Zhang, Xueyan, Wang, Huimin, Han, Baohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347752/ https://www.ncbi.nlm.nih.gov/pubmed/27811371 http://dx.doi.org/10.18632/oncotarget.13031 |
Ejemplares similares
-
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
por: Zhang, Yanwei, et al.
Publicado: (2020) -
Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021) -
Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
por: Zhang, Xueyan, et al.
Publicado: (2018) -
Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma
por: Hu, Minjuan, et al.
Publicado: (2020) -
Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)